Mehmet Altan

The University of Texas MD Anderson Cancer Center

Also affiliated with Ankara University, University of Health Science, Sağlık Bilimleri Üniversitesi, University of Health Sciences Antigua

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

1in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 36 papers. Top paper: “Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status”.

Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

Journal of Thoracic Oncology(2021)10.1016/j.jtho.2021.10.013

N/A

8.9DataRank · unranked

377 citations

Kathryn C. Arbour, W. Marston Linehan, Amir Vajdi, Natalie I. Vokes, Lingzhi Hong +28 more

Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.04.026

N/A

6.8DataRank · unranked

195 citations

Marcelo V. Negrão, Seyedeh Dibaj, Runzhe Chen, Alexandre Reuben, Jadi M. Bohac +32 more

Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial

The Lancet(2023)10.1016/s0140-6736(23)01384-3

N/A

5.0DataRank · unranked

230 citations

Steven H. Lin, Wenli Dong, Zhongxing Liao, Saumil Gandhi, Carl M. Gay +23 more

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001001

N/A

4.9DataRank · unranked

289 citations

Hari Menon, Dawei Chen, Vivek Verma, Chad Tang, Mehmet Altan +12 more

Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial

Nature Medicine(2023)10.1038/s41591-022-02189-0

N/A

4.1DataRank · unranked

213 citations

Cheuk Hong Leung, Annikka Weissferdt, Apar Pataer, Brett W. Carter, Myrna C. B. Godoy +52 more

Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

Cancer Cell(2022)10.1016/j.ccell.2022.06.006

N/A

3.9DataRank · unranked

106 citations

Jacqulyne Robichaux, Brett W. Carter, Mehmet Altan, Hai T. Tran, Don L. Gibbons +22 more

Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience

The Oncologist(2023)10.1093/oncolo/oyad118

N/A

0.768DataRank · unranked

26 citations

Felipe Soto, Linda Zhong, Fechukwu Akhmedzhanov, Nathaniel R. Wilson, Abdulrazzak Zarifa +23 more

Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy

Nature Communications(2022)10.1038/s41467-022-29539-3

N/A

0.716DataRank · unranked

117 citations

Yanshuo Chu, Mercy Misoi, María E. Suarez‐Almazor, Jean Tayar, Huifang Lu +33 more

Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

Nature Communications(2024)10.1038/s41467-024-47512-0

N/A

0.672DataRank · unranked

87 citations

Muhammad Aminu, Tatiana V. Karpinets, Pingjun Chen, Maliazurina B. Saad, Morteza Salehjahromi +32 more

Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status

Journal for ImmunoTherapy of Cancer(2020)10.1136/jitc-2020-001007

N/A

0.614DataRank · unranked

59 citations

Biagio Ricciuti, E. Jimenez-Aguilar, Fangxin Hong, Zihan Wei, Mizuki Nishino +10 more

Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial

Lung Cancer(2022)10.1016/j.lungcan.2022.10.006

N/A

0.529DataRank · unranked

33 citations

Luyang Yao, Neda Kalhor, Brett W. Carter, Mehmet Altan, George Blumenschein +14 more

High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2024-008950

N/A

0.515DataRank · unranked

13 citations

Ruoxing Li, Ziyi Li, Runzhe Chen, Ajay Sheshadri, Hai T. Tran +12 more

Comparison of imaging based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed paraffin-embedded tumor samples

Nature Communications(2025)10.1038/s41467-025-63414-1

N/A

0.494DataRank · unranked

26 citations

Max Molina Ayala, Sharia Hernandez, Wei Lu, Khaja Khan, Alejandra G. Serrano +69 more

Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non–small cell lung cancer

Cancer(2023)10.1002/cncr.34820

N/A

0.488DataRank · unranked

9 citations

Janet Tu, Denái R. Milton, Bülent Yılmaz, Yanyan Tian, Frank V. Fossella +8 more

Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial

Scientific Reports(2022)10.1038/s41598-022-16588-3

N/A

0.375DataRank · unranked

4 citations

David S. Hong, Christine B. Peterson, Bettzy Stephen, Ecaterina E. Dumbrava, Shubbam Pant +18 more

Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events

Frontiers in Immunology(2023)10.3389/fimmu.2023.1322818

N/A

0.357DataRank · unranked

6 citations

Quan‐Zhen Li, Qi Wang, Natalie I. Vokes, Ajay Sheshadri, Jianjun Gao +14 more

Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept

Frontiers in Immunology(2023)10.3389/fimmu.2023.1249511

N/A

0.345DataRank · unranked

9 citations

Naval Daver, Myrna C. B. Godoy, Girish S. Shroff, Carol C. Wu, Luis F. Torre-Sada +19 more

Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases

OncoImmunology(2023)10.1080/2162402x.2023.2261264

N/A

0.330DataRank · unranked

8 citations

Sabina Sandigursky, Juhee Song, María A. López-Olivo, Houssein Safa, Samuel Cytryn +12 more

Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC

Nature Communications(2025)10.1038/s41467-025-61823-w

N/A

0.312DataRank · unranked

7 citations

Qasem Al-Tashi, Lingzhi Hong, Vivek Verma, Wentao Li, Daniel Boiarsky +32 more

Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma

Radiotherapy and Oncology(2024)10.1016/j.radonc.2024.110121

N/A

0.304DataRank · unranked

5 citations

Ting Xu, Yuki Sasaki, Ruitao Lin, Aileen B. Chen, James W. Welsh +18 more

Safety and Tolerability of Letetresgene Autoleucel (GSK3377794): Pilot Studies in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1591

N/A

0.292DataRank · unranked

6 citations

Gilberto Lopes, T. Jeroen N. Hiltermann, Ramaswamy Govindan, Liza C. Villaruz, Emiliano Calvo +19 more

Comparison of imaging-based single-cell resolution spatial transcriptomics profiling platforms using formalin-fixed, paraffin-embedded tumor samples

Research Square(2025)10.21203/rs.3.rs-5656204/v1

N/A

0.104DataRank · unranked

1 citations

Nejla Ozirmak Lermi, Max Molina Ayala, Sharia Hernandez, Wei Lu, Khaja Khan +25 more

Impact of Co-mutations and Transcriptional Signatures in Non–Small Cell Lung Cancer Patients Treated with Adagrasib in the KRYSTAL-1 Trial

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-24-2310

N/A

0DataRank · unranked

21 citations

Alvaro G. Paula, David Molkentine, Laura D. Hover, Monique B. Nilsson, Natalie I. Vokes +17 more

Rapid Intracranial Response With Tarlatamab in Patients With Untreated Brain Metastases From SCLC—A Real-World Case Series: Case Report

Journal of Thoracic Oncology(2025)10.1016/j.jtho.2025.02.023

N/A

0DataRank · unranked

17 citations

Komal Shah, Mitchell Parma, Kaiwen Wang, Eric K. Singhi, Whitney E. Lewis +23 more

Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases

Research Square(2022)10.21203/rs.3.rs-2372243/v1

N/A

0DataRank · unranked

1 citations

Malek Shatila, Cynthia Liu, Jianbo Wang, Mehmet Altan, Hao Chi Zhang +3 more

Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC

Journal of Thoracic Oncology(2020)10.1016/j.jtho.2020.08.022

N/A

0DataRank · unranked

98 citations

John V. Heymach, Chunxiao Guo, Hari Menon, Katherine Klein, Taylor R. Cushman +19 more

Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis

Journal for ImmunoTherapy of Cancer(2023)10.1136/jitc-2023-007195

N/A

0DataRank · unranked

28 citations

Fangwen Zou, Sienna Durbin, Barbara E. Dutra, Hamzah Abu‐Sbeih, Anusha Shirwaikar Thomas +11 more

Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer

Radiotherapy and Oncology(2022)10.1016/j.radonc.2022.10.002

N/A

0DataRank · unranked

19 citations

Lirong Wu, Saumil Gandhi, Jing Wang, Quyhn-Nhu Nguyen, Aileen B. Chen +8 more

Pneumonitis After Concurrent Chemoradiation and Immune Checkpoint Inhibition in Patients with Locally Advanced Non-small Cell Lung Cancer

Clinical Oncology(2023)10.1016/j.clon.2023.07.003

N/A

0DataRank · unranked

20 citations

Felipe Soto, Ting Xu, Nathaniel R. Wilson, Maria Franco-Vega, C.A. Simbaqueba Clavijo +18 more

Case Report: Immune checkpoint inhibitor–induced multiorgan vasculitis successfully treated with rituximab

Frontiers in Nephrology(2023)10.3389/fneph.2023.1168614

N/A

0DataRank · unranked

5 citations

Naszrin Arani, Vishnu P. Parvathareddy, Amanda Tchakarov, Maen Abdelrahim, María E. Suarez‐Almazor +6 more

Physician Views on the Provision of Information on Immune Checkpoint Inhibitor Therapy to Patients with Cancer and Pre-Existing Autoimmune Disease: A Qualitative Study

Cancers(2023)10.3390/cancers15102690

N/A

0DataRank · unranked

6 citations

Gabrielle F. Duhon, Juan Ignacio Ruiz, Mehmet Altan, Hussein A. Tawbi, Adi Diab +6 more

A novel statistical method for decontaminating T-cell receptor sequencing data

Briefings in Bioinformatics(2023)10.1093/bib/bbad230

N/A

0DataRank · unranked

3 citations

Mehmet Altan, Alexandre Reuben, Ruitao Lin, John V. Heymach, Hai T. Tran +6 more

910 Development and user testing of a website with information for cancer patients who have pre-existing autoimmune disease and are considering immune checkpoint inhibitors (ICIs)

Regular and Young Investigator Award Abstracts(2023)10.1136/jitc-2023-sitc2023.0910

N/A

0DataRank · unranked

0 citations

María E. Suarez‐Almazor, Gabrielle F. Duhon, McKenna Erck, Cassandra Calabrese, Mehmet Altan +7 more

Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC

JTO Clinical and Research Reports(2022)10.1016/j.jtocrr.2022.100391

N/A

0DataRank · unranked

42 citations

Ting Xu, Lirong Wu, Pablo B. Lopez, Clemens Grassberger, Susannah G. Ellsworth +9 more

Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies

Journal of Immunotherapy and Precision Oncology(2024)10.36401/jipo-24-12

N/A

0DataRank · unranked

9 citations

Saadia A. Faiz, Mehmet Altan, Ajay Sheshadri, Kathy L. Chan

Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study

Oral Oncology(2024)10.1016/j.oraloncology.2024.106747

N/A

0DataRank · unranked

2 citations

S. Liu, Priya Bhosale, Mehmet Altan, W. Darbonne, Katja Schulze +14 more